Finoriq research workspace
Aquestive Therapeutics, Inc. (AQST) Company Overview
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. Review AQST filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
- Company
- Aquestive Therapeutics, Inc. (AQST)
- Ticker
- AQST
- Market Cap
- $497.5M
- Latest Price
- $3.965
- Industry
- Biotech & Pharma
Aquestive Therapeutics, Inc. (AQST) Current Valuation Metrics
Static valuation preview for Aquestive Therapeutics, Inc. (AQST). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 10.6x | Revenue | TTM Q1 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | -12.9% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -8.2% | Operating Cash Flow | TTM Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.